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Currently available vaccines have similar efficacy if they are matched
to the most prevalent circulating strains. They also have comparable
adverse effect profiles. The choice of a specific preparation of
vaccine therefore requires consideration of cost, purity of the vaccine
preparation in terms of the amount of egg protein and endotoxin,
allergy to different constituents of the vaccine, reactogenicity profiles,
as well as the preferred route of administration. Intradermal
injection of the vaccine appears to be a viable alternative to the
traditional intramuscular administration with the additional benefit
of requiring a smaller volume of vaccine. Despite the documented
benefits in various community and institutional settings, influenza
vaccination has been underutilised by most target groups. A
major obstacle to broader coverage of vaccination is the perceived
ineffectiveness of the vaccine and the relatively benign nature of the
illness in most patients. Uptake of vaccine among target populations,
especially health care workers, needs to be improved through a
concerted effort between frontline clinicians and health authorities.
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Introduction
Influenza is one of the most common infectious diseases and possesses
high epidemic and pandemic potential. It is largely a vaccine-preventable
disease. Influenza vaccine differs from other currently available vaccines
in being a trivalent vaccine and in that the vaccine composition needs to
be updated annually.
Orthomyxoviridae is a family of single-stranded minus-sense RNA
viruses with a segmented genome. The three medically important genera
are Influenzavirus A, Influenzavirus B, and Influenzavirus C. The eight
RNA segments of the influenza A virus genome encode 10 proteins:
polymerase proteins (PB1, PB2, and PA), nucleocapsid protein (NP),
haemagglutinin protein (HA), neuraminidase (NA), matrix proteins (M1
and M2), and non-structural proteins (NS1 and NS2).1 Currently, 16 HA
and 9 NA types are recognised. The HA mediates viral attachment and
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cellular entry and is the main viral target of protective
humoral immunity. The antibody titre against HA is
commonly used as a surrogate marker of immunity
and to compare the immunogenicity of different vac-
cine preparations. Neuraminidase facilitates the spread
of the virions in the host and is the target of NA inhibi-
tors (oseltamivir and zanamivir) which are active
against both influenza A and B viruses. The M2 pro-
tein serves as an ion channel. It is important in the
uncoating of viruses in endosomes and in viral assem-
bly, and is the target of amantadine and rimantadine.
Influenza A virus is prone to undergo antigenic
variations (antigenic drift and antigenic shift).
Antigenic drift occurs all the time and explains the
need for yearly changes in vaccine composition.
Antigenic shift results in the appearance of a novel
combination of HA and NA for which the human
population has little or no immunity, or when a virus
acquires the ability to directly infect humans from their
natural animal hosts, especially the avian species.
Properties of influenza vaccines
Vaccine strains
Most of the currently available influenza vaccines are
inactivated vaccines. A live attenuated vaccine was
approved by the United States Food and Drug Admin-
istration (FDA) in 2003. Recommendations on
vaccine composition are based on the constant year-
round global influenza surveillance coordinated by the
World Health Organization (WHO). Two influenza
A strains (currently H1N1 and H3N2) and one influ-
enza B strain are chosen, based on their global
prevalence. Every year in February (for the northern
hemisphere), the WHO recommends the composition
of influenza virus vaccines for use in the following
influenza season (normally from November to April).
Similar recommendations are made for the southern
hemisphere in September every year for the forthcom-
ing influenza season (from May to September in the
following year). As an example, the vaccine to be used
in the 2005 to 2006 season (northern hemisphere)
contains an A/New Caledonia/20/99(H1N1)-like
virus, an A/California/7/2004(H3N2)-like virus, and a
B/Shanghai/361/2002-like virus.2 In tropical countries,
influenza occurs throughout the year and the choice
of vaccine composition requires correlation with local
epidemiology so that the most appropriate vaccine
can be chosen. Some of the more commonly used
vaccines are listed in Table 1.3,4
Inactivated vaccine production
Vaccine strains of influenza viruses are cultured in
allantoic cavities of embryonated hens eggs. This
conventional method of viral culture has disadvantages,
including dependence on high-quality eggs, relatively
cumbersome processing and disinfection, alteration in
the antigenicity of the progeny viruses when grown in
avian tissues, and potential adverse reactions when
used in individuals with egg allergy. In recent years,
attempts have been made to prepare influenza vaccines
in mammalian cell lines, especially the Madin-Darby
canine kidney (MDCK) and African green monkey
kidney (Vero) cell lines.5 Successful development of
cell culture–derived vaccines may improve vaccine
availability during pandemics. Cell culture–derived
vaccines also preserve the antigenic properties of
clinical isolates of influenza viruses better and elicit
a stronger cell-mediated immunity than conventional
egg-derived vaccines.6
Viral particles harvested from the growth substrate
are inactivated by formalin or β-propiolactone. The
virions are ‘split’ (using solvents to disrupt the
viral envelope) to produce subvirions. These
split-virion vaccines retain the immunogenicity of
the virus, while the reactogenicity is reduced com-
pared with whole-virus vaccines because of a lower
quantity of non-viral components (eg egg proteins)
and non-essential viral components (proteins and
lipid membrane). Subunit vaccines are produced by
further zonal centrifugation to separate the surface
antigens from other viral proteins. The main immuno-
gen of these vaccines is the HA. One adult dose of
vaccine contains 15 µg of HA per viral strain.
Live attenuated vaccines
FluMist (MedImmune, Gaithersburg [MD], US) is the
only FDA-approved live attenuated influenza vaccine
available at present. It is delivered by intranasal
spray to simulate a natural infection. A syringe-like
applicator is used to produce large aerosols and
delivers 0.25 mL of the vaccine into each nostril
(total volume, 0.5 mL). Attenuation is achieved by
cold-adaptation of master donor viruses, followed
by reassortment with contemporary vaccine strains
to produce the trivalent cold-adapted influenza
vaccine (CAIV-T).7 Cold-adapted viruses can only
replicate in the upper respiratory epithelium at a
temperature of about 32ΟC to 33ΟC. In contrast to
inactivated vaccines, CAIV-T also stimulates the
production of secretory immunoglobulin A (IgA)
antibody and elicits cell-mediated immunity. The
serum haemagglutinin antibody level achieved
after vaccination with CAIV-T is lower than that of
inactivated vaccines, despite similar efficacy between
the two types of vaccines.8
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Adjuvants
Two adjuvants have been used in inactivated vaccines
to boost their immunogenicity. These are MF59 (an
oil-in-water emulsion containing squalene, polysorb-
ate 80, and sorbitan trioleate) and immunopotentiating
reconstituted influenza virosomes (IRIVs). The
MF59-adjuvanted influenza vaccine (Fluad; Chiron
Vaccines, Emeryville [CA], US) is more immunogenic
than non-adjuvanted vaccines with a higher post-
vaccination geometric mean titre of haemagglutinin
antibody, though the overall seroconversion rate is
similar.9,10 Fluad, however, has a significantly higher
reactogenicity than other vaccines in terms of local
symptoms.
The IRIVs utilise a liposomal carrier system
consisting of spherical, unilamellar vesicles, with an
average diameter of about 150 nm.11 The virosomes
are produced by detergent solubilisation of whole
virions, followed by purification and mixture with
phospholipids (lecithin and a small proportion of viral
phospholipids). About 70% of the virosome is made
up of phosphatidylcholine, while the rest is derived
from the original viral envelopes which carry the
antigenic surface proteins HA and NA. The virosomes
enter antigen-presenting cells in a way similar to
natural infection by influenza viruses: HA-mediated
endocytosis, conformational change of HA in
endosomes, fusion of the virosome membrane with
the endosomal membrane, and presentation of
antigens to major histocompatibility complex
(MHC) class I and II molecules. This more natural
means of antigen presentation and concomitant
activation of MHC class I and II pathways accounts
for the excellent immunogenicity of the vaccine. The
vaccine (Inflexal V; Berna Biotech, Bern, Switzerland)
is free from preservatives and detergents and has a
lower level of ovalbumin than conventional vaccines
(Table 211-14). The virosome subunit vaccine is as
immunogenic as conventional vaccines but with a sub-
stantially lower incidence of local adverse events.15
Chemical contents and impurities
Different preparations of vaccines show remarkable
variations in their chemical composition (Table 2). The
subunit vaccines generally have a lower total protein
content than split-virion vaccines. However, this lower
protein content does not always equate with higher
purity, as some subunit formulations have a substan-
tially higher egg protein content than comparators.
The amount of non-viral components (eg endo-
toxin, ovalbumin) in the vaccine may be related to
the adverse reaction profiles. In this regard, the IRIV
vaccine has the lowest non-viral component content.
Other vaccine excipients
Aminoglycosides, formalin or β-propiolactone may be
present in vaccines but are generally reduced to trace
quantities or below detection limits. Thimerosal (a
mercurial compound) is commonly used as an
antimicrobial and preservative in many vaccines,
especially in multi-dose vials (often at a concentration
of 25 µg per 0.5 mL dose). It may be present in trace
amounts in some preparations.
Schedule and route of administration
The usual vaccination regimen is one yearly dose to
be given at least 1 to 2 months prior to the expected
onset of the influenza season. Two doses are given
1 month apart for children under 9 years if they have
not been vaccinated previously. The recommended
route of administration for inactivated vaccines is
intramuscular injection, usually in the deltoid for
adults. FluMist is administered as a nasal spray.
Prior to the licensing of FluMist, another nasally
administered trivalent inactivated vaccine consisting
of virosomes (Nasalflu; Berna Biotech, Bern,
Switzerland) had been marketed in Switzerland
since 2000.16 This vaccine was withdrawn from
the market in 2001 because of a possible association
with facial paralysis.
Choosing individual preparations of
influenza vaccine
All currently available vaccines have comparable
efficacy and adverse reaction profiles when properly
administered and if they match the circulating viral
strains.17 Therefore, if a specific preparation is to be
chosen, other factors need to be taken into account.
Cost is an important consideration, especially in bulk
purchasing for large organisations or health authorities.
For the individual, one needs to consider the presence
of excipients to which they may be allergic, the
chemical composition of individual preparations
(especially the content of non-viral components and
endotoxin, and the presence of preservatives), the
relative frequency of adverse reactions, underlying
medical conditions which preclude the use of live
attenuated vaccines, and the preferred route of
administration, if intranasal vaccines are available
locally.
Adverse reactions to vaccination
The most common adverse events to inactivated
influenza vaccines are local inflammatory reactions
such as pain, erythema, and induration. These occur
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in up to 65% of recipients and are usually mild
and self-limiting, lasting for 1 to 2 days. Systemic
reactions including fever, myalgia, arthralgia, and
headache may appear 6 to 12 hours after vaccination
and last for 1 to 2 days. They occur at a frequency of
1% to 5%. Treatment is usually not necessary. Oral
paracetamol may be used if symptoms are severe.
Subunit vaccines (with the exception of the MF59-
adjuvanted vaccine) have a significantly lower
incidence of local and systemic reactions compared
with split-virion and whole-virus vaccines.17
An unusual complication of inactivated influenza
vaccination is the oculo-respiratory syndrome (ORS),
first described in Canada in the 2000 to 2001 season,
with 960 cases reported at that time.18 Symptomatol-
ogy of ORS includes respiratory symptoms (84%;
cough, dyspnoea, chest tightness, wheezing, etc),
ocular symptoms (55%; bilateral red eyes, discharge,
itchiness, pain, blurred vision), oedema (33%;
palpebral, mouth, lips, tongue, facial), and systemic
upsets (fever, myalgia, headache, fatigue, chills,
gastro-intestinal problems).19 The syndrome lasted
for 48 hours or less in 69% of cases, 3 to 7 days in
22%, over 1 week in 8%, and over 1 month in 3%.19
Antihistamines were used by some patients for
symptomatic control. The syndrome was associated
with one particular preparation of split-virion vaccine
(Fluviral S/F; Shire Biologics, Ville St Laurent,
Quebec, Canada) which accounted for 96% of cases.
Electron microscopy of Fluviral S/F showed that
13% to 33% of the virions were unsplit, compared
with a figure of 2% for contemporary vaccines.20 The
unsplit virions formed large aggregates, believed to be
the cause of the syndrome. Recurrence of ORS on sub-
sequent influenza vaccination can occur but symptoms
of recurrence noted have been mild and did not pre-
clude further influenza vaccination.20 It seems that
Table 1.  Properties of some currently available influenza vaccines
Trade name Manufacturer Registration in List price* Type of vaccine
Hong Kong3 (HKD per 0.5 mL dose)4
Agrippal S1 Chiron Yes 35 Subunit, inactivated
Fluad Chiron Yes Not available Subunit, inactivated
Fluarix GlaxoSmithKline Yes 148 Split-virion, inactivated
Fluvax CSL Yes 75 Split-virion, inactivated
Inflexal V Berna Biotech Yes 108 Virosome subunit, inactivated
Influvac Solvay Yes 70 Subunit, inactivated
Vaxigrip Aventis Pasteur Yes 58 Split-virion, inactivated
FluMist MedImmune No Not available Live attenuated
* Actual price may differ; information from Drug Education Resources Centre, Society of Hospital Pharmacists of Hong Kong
† Information from package insert of the vaccines and Drug Education Resources Centre, Society of Hospital Pharmacists of Hong Kong
Table 2.  Comparison of the chemical composition of some influenza vaccines*
Trade name Type of vaccine Haemagglutinin Haemagglutinin titre Neuraminidase activity
protein content (mU per 0.5 mL dose)
(µg per 0.5 mL dose)
Agrippal S1 Subunit 58 1:6400 1 0.4
Begrivac Split-virion 38 1:6400 1 0.5
Fluarix/Influsplit Split-virion 56 1:6400 1 0.6
Fluvirin Subunit 37 1:400 11 -
Inflexal V Virosome subunit - - -
Influvac Subunit 33 1:12 800 1.5
Vaxigrip Split-virion 45 1:12 800 0.5
* Data for vaccines other than Inflexal V are from Chaloupka et al12; data for Inflexal V are from Mischler and Metcalfe11
† Upper limits for inactivated split-virion and subunit vaccines for ovalbumin, <1 µg per human dose; bacterial endotoxin, <100 IU per
human dose13,14; upper limit of ovalbumin for virosome vaccine (Inflexal V), <50 ng per human dose14
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complications compatible with ORS may have oc-
curred in Europe and the United States in the 1990s.21
Guillain-Barré syndrome (GBS) is one of the
more serious, though rare, potential adverse reactions
following influenza vaccination. The association was
first noted in 1976 to 1977, with a relative risk ranging
from 3.96 to 7.75 for the 6-week period following
vaccination.22 The relative risk ranged from 0.6 to 1.5
in the seasons from 1978 to 1979 and 1993 to
1994.23,24 The incidence of post-influenza vaccination
GBS appeared to have a decreasing trend in the United
States from 1993-1994 (1.7 per million vaccinations)
to 2002-2003 (0.4 per million vaccinations).25
Autoimmune damage induced by endotoxin or other
cellular components of bacteria (eg Salmonella and
Campylobacter which also have a zoonotic reservoir
in poultry) and egg proteins have been postulated to
contribute to the development of GBS.
Intranasal administration of influenza vaccines is
generally well-tolerated. FluMist has been associated
with an increased risk of asthma in young children
aged 18 to 35 months.26 Other studies in older
children with stable moderate-to-severe asthma
have not shown significant worsening of asthma,
however.27 Use of CAIV-T in patients with asthma
should be avoided for the time being. Musculoskeletal
pain, lymphadenopathy, otitis media with effusion,
rhinorrhoea, and nasal congestion have occurred
following the use of FluMist.
Efficacy of vaccination
Outcome measures used in different vaccine efficacy
studies have varied widely. Parameters measured
have included serological- or culture-confirmed cases
of influenza, influenza-like illness, influenza-related
hospitalisations, complications, or deaths. In general,
Growth Adjuvant Recommended Thimerosal† Other excipients listed
substrate route of administration (other than buffers and salts)†
Eggs Nil Intramuscular 0.5 µg/dose Not listed
Eggs MF59 Intramuscular Not listed Formaldehyde, cetyltrimethyl-
ammonium bromide, sucrose,
kanamycin, neomycin
Eggs Nil Intramuscular Residual amount Formaldehyde, gentamicin,
Tween 80, octoxynol 9, sucrose,
sodium deoxycholate
Eggs Nil Intramuscular Not listed Neomycin, polymyxin, sucrose,
sodium taurodeoxycholate
Eggs Immunopotentiating Intramuscular Nil Lecithin
reconstituted
influenza virosomes
Eggs Nil Intramuscular Nil Not listed
Eggs Nil Intramuscular 2 µg/dose Triton X-100, sucrose, neomycin,
formaldehyde (≤30 µg)
Eggs Nil Intranasal spray Nil Not listed
Neuraminidase/ Matrix protein Viral protein per total Ovalbumin content† Endotoxin content†
nucleocapsid content vaccine protein (%) (ng per 0.5 mL dose) (IU per 0.5 mL dose)
protein content (µg per 0.5 mL dose)
(µg per 0.5 mL dose)
- - 81 13511. 1<0.51
18 1 80 1111v. 1<1.01
27 6 89 11011. 1<0.51
14 - 88 11011. 1<4.61
- - - 111.85 1<0.55
- - 61 32511. 1<0.91
22 7 80 11111. <64.01
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higher vaccine efficacy has been seen when more
specific outcomes (eg laboratory-confirmed cases of
influenza) are measured. Vaccine efficacy, as deter-
mined by several large meta-analyses, is summarised
in Table 3.28-31 The level of protection achieved is also
higher when the vaccine strains match the prevailing
epidemic strains of viruses.29
At 7 days’ post-vaccination, 59% to 100% of
recipients have been shown to have developed
protective levels of antibody, with the antibody titre
peaking between day 14 and 21.32 At 280 days’
post-vaccination, 71% to 100% of recipients still
had protective antibody titres. Levels of antibody and
duration of protection wane with time at variable rates.
In otherwise healthy young adults, protection lasts for
more than 1 year, with a 68% to 75% reduction in
laboratory-confirmed influenza infection observed 1
year after vaccination.
Influenza vaccination: controversies and
policies
Could vaccines be administered by other routes?
The subcutaneous route may be more reactogenic and
less immunogenic than the intramuscular route but
current evidence is inconclusive.33 Patients receiving
anticoagulant therapy had been given intramuscular
vaccination without an increased incidence of
haemorrhagic complications.34 The intradermal route
was recently re-examined as an alternative in two
studies which employed different vaccine prepara-
tions.35,36 Kenney et al35 used one fifth of the dose
(0.1 mL) of a standard inactivated vaccine (Fluvirin;
Evans Vaccines, Liverpool, UK) in a population aged
19 to 41 years. Belshe et al36 used a specially prepared
formulation which contained 40% of the usual intra-
muscular dose in 0.1 mL volume. This study popula-
tion included subjects of over 60 years of age. In
both studies, immunogenicity was similar for both
intramuscular and intradermal routes, but local
reactions were significantly more common after
intradermal injection. The intradermal route has been
shown to be a viable and valuable alternative to
other parenteral (mainly intramuscular) routes of
vaccination, most notably in the case of rabies
vaccines,37 in which substantial cost-saving can be
achieved in resource-limited situations without
compromising vaccine efficacy. Intradermal injection,
however, requires a higher level of technical compe-
Table 3.  Summary of meta-analyses and reviews on influenza vaccine efficacy studies
Population No. of clinical Outcomes: efficacy Other findings (95%
trials reviewed; (95% confidence interval) confidence interval)
years conducted
Healthy children, 13; 1985-2001 Culture-confirmed influenza: No difference in efficacy between
aged ≤18 years28 74% (57-84%) inactivated vs live attenuated
Serologically confirmed influenza: vaccines:
59% (43-71%) QCulture-confirmed influenza:
ILI*: 33% (29-36%) Q65% (45-77%) vs
Q80% (53-91%)
QSerologically confirmed
Qinfluenza: 63% (43-76%) vs
Q54% (20-74%)
QILI: 33% (22-42%) vs
Q34% (31-38%)
Healthy adults29 39; 1966-1995 Inactivated vaccines -
QILI: 24% (15-32%)
QSerologically confirmed
Qinfluenza: 68% (49-79%)
Live attenuated vaccines
QILI: 13% (5-20%)
QSerologically confirmed
Qinfluenza: 48% (24-64%)
Elderly, aged ≥65 years; 20; 1968-1989 ILI: 56% (39-68%) No significant difference in
mean or median age, ≥80 Pneumonia: 53% (35-66%) efficacy when the epidemic
years30. All studies except Hospitalisation: 48% (28-65%) strain was a drift variant from
one involved institutionalised Death: 68% (56-76%) the vaccine strain
elderly patients
Elderly, aged ≥65 years, 15; 1965-1996 ILI: 35% (19-47%) -
living in the community31 Hospitalisation: 33% (27-38%)
Death: 47% (25-62%)
* ILI influenza-like illness
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tence for administration than the intramuscular
route. If the efficacy of intradermal vaccination is
confirmed by future studies, its dose-sparing property
could be a major benefit, especially in pandemic
situations or at times of vaccine shortage.
Are booster doses of value in the elderly?
Elderly people (≥65 years) are commonly believed to
respond less well to influenza vaccination than
younger adults. However, a poorer antibody response
in the elderly has not been universally observed.38
An extensive review of studies has failed to show a
significant inferiority of immune response among
the elderly following influenza vaccination, but a
tendency to better response in the younger population
was observed.39 The use of a booster dose or a double-
dose of vaccine has been trialled in the elderly. The
effectiveness of these approaches was again conflicting,
with variable degrees of augmentation of the immune
response being observed.40-43 It is difficult to recom-
mend such approaches in general because it is impos-
sible to predict who may benefit from a booster. In
addition, a routine booster dose would entail a
substantial increase in the demand for vaccines.
Does vaccination work in immunocompromised
individuals?
Individuals with chronic medical conditions may
respond less favourably to influenza vaccination.
Patients on haemodialysis, for example, were shown
to develop a lower post-vaccination antibody titre than
healthy controls, but still had a 23% to 44% response
rate and a 46% to 87% protection rate after vaccination.44
A booster dose 8 weeks later was shown to increase
the response and protection rates slightly but is not
generally recommended. Patients with diabetes
likewise have a lower response rate but similar post-
vaccination protection rates when compared with
healthy controls.45
In HIV-infected individuals, the CD4 count gen-
erally correlates with the response to the vaccine;
patients with CD4 counts of less than 100 x 106 /L
were shown to have severely impaired antibody re-
sponses which were not improved by booster doses.46
For transplant recipients, lower seroconversion and
protection rates are commonly observed.47 In bone
marrow transplant recipients, vaccine responsiveness
is usually restored at 2 years post-transplant, unless
there is concomitant graft-versus-host disease. Among
solid organ transplant recipients, recipients of a renal
transplant (43-58%) appeared to have a higher sero-
conversion rate compared with recipients of heart
(21-53%), lung (0-13%) or liver transplants (15-31%).48
The safety of CAIV-T in pregnant women and in
immunocompromised individuals requires further
study, although it has been given to apparently healthy
HIV-infected patients without significant adverse
effects.49 The latest guideline from the United States
Centers for Disease Control and Prevention (CDC)
recommends against the use of CAIV-T in a number
of patient groups including patients with asthma,
reactive airway diseases, other chronic pulmonary and
cardiovascular diseases, underlying medical conditions
such as diabetes mellitus, renal dysfunction, or
haemoglobinopathies, and individuals with known or
suspected immunodeficiency diseases or who are
receiving immunosuppressive therapies. Additional
groups are children or adolescents receiving aspirin or
other salicylates (Reye’s syndrome is associated with
wild-type influenza infection), individuals with a
history of GBS, and pregnant women.50
Does thimerosal in vaccines pose any health risk?
The use of thimerosal has raised safety concerns,
especially in relation to use in children and infants.
There is currently no evidence for a causal relation-
ship between exposure to thimerosal in vaccines and
adverse health effects, with the exception of the
rare occurrence of hypersensitivity reactions.51
Nevertheless, there have been moves towards the use
of ‘preservative-free’ (<1 µg thimerosal per 0.5 mL
dose) influenza vaccines in some countries.50
Can patients with egg allergy be vaccinated?
The main absolute contra-indication is an anaphylac-
tic reaction towards the vaccine. Anaphylactic reac-
tions towards aminoglycosides, latex, and thimerosal
are theoretical risks but these have not been reported
in association with influenza vaccines. Thimerosal
allergy may present as delayed-type or immediate
(IgE-mediated) hypersensitivity reactions, with the
former being more common.52 Patch tests and intra-
dermal tests to thimerosal could be performed but these
are considered to be poor predictors of the likelihood
of reaction to thimerosal-containing vaccine.52
The egg protein content of available influenza
vaccines has been reported to vary from 0.02 to
42 µg/mL.53,54 Egg-derived vaccines, such as the
measles-mumps-rubella vaccine, have been given to
children with severe egg allergy without adverse
reactions.55 Influenza vaccines could also be
administered to these children safely, including
some with anaphylactic reactions to eggs.53 A skin
patch test to egg and skin testing of influenza vaccine
could be performed. Those found to have a positive
skin test towards the influenza vaccine could then
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either opt for chemoprophylaxis (if necessary), to
receive the usual regimen for influenza vaccination
under specialist supervision, or to undergo a desensi-
tisation protocol.54 Cell culture–derived vaccine will
be an alternative in the future.
General policies for influenza vaccination
Vaccination programmes usually attempt to achieve
three objectives—individual protection (eg to prevent
the disease and its complications in high-risk
individuals), prevention of institutional outbreaks of
the disease which may in turn affect high-risk patients
and staff (eg immunisation of health care workers and
residents of long-term care facilities), and reduction
of the burden of disease in the community setting as a
public health measure (eg vaccination of young
children). These objectives are reflected in the target
groups specified in various national guidelines. In most
guidelines, the key target groups include:
(1) elderly people, usually defined as persons aged
65 years and above (in the United States in 2000,
this age limit was reduced to above 50 years);
(2) residents of long-term care facilities;
(3) adults and children suffering from chronic diseases
including respiratory, cardiovascular, metabolic,
or renal diseases; haemoglobinopathy, or
immunosuppression;
(4) children receiving long-term aspirin therapy (in
order to minimise the risk of Reye’s syndrome);
(5) pregnant women; and
(6) health care workers and workers in long-term care
facilities.50
Vaccination of health care workers has been shown
to be associated with a significant decrease in patient
mortality.56 Since 2004, young children aged 6 to 23
months have also been included as a target group for
influenza vaccination by the CDC.50
Although influenza vaccination is effective in the
prevention of infection, routine yearly vaccination of
all otherwise healthy adults has not been deemed
cost-effective.57 In addition to the limitation in the
supply of vaccines to achieve such a goal, studies have
not been able to show benefits of such an approach in
significantly reducing the spread of the disease, the
economic loss (as measured by working days lost;
only minimal reductions were demonstrated), and
in reducing morbidity and hospitalisation (likely to
be related to the lower complication rates in
this population compared with the elderly). It
was therefore suggested that the limited resources
available should not be directed toward mass
vaccination for public health reasons, although the
vaccine may still be offered to individuals for
individual protection.
Vaccination recommendations in Hong Kong
The target groups for influenza vaccination in
Hong Kong presently include elderly people living
in residential care homes, residents of institutions
for the disabled, elderly people aged 65 years or
above, those with underlying medical conditions
(similar to CDC recommendations), health care
workers, children aged 6 to 23 months, and poultry
workers.58
Farmers and workers in the poultry industry
represent a special target group in high-risk areas
for avian influenza, including Hong Kong.59 This
issue was raised following the latest avian influenza
epidemic in Southeast Asia that started in late 2004.
Vaccination against human influenza, though not
protective against avian strains of the virus, has the
theoretical benefit of reducing the chance that these
individuals will be co-infected with an avian and a
human virus, thereby allowing genetic reassortment
to occur.
Improving influenza vaccine coverage
Although influenza vaccination has proven clinical
and epidemiological benefits, its uptake in the general
population and among health care workers has
generally been suboptimal. In the United States, the
vaccination rate among health care workers was
10% in 1989, 34% in 1997, and 40% in 2003. The
vaccination rate in other target groups is also below
50%.60 Common reasons for non-uptake include
concern about side-effects, doubts regarding the
efficacy of the vaccine, perception of seriousness
of influenza, the individual’s health, and lack of
information from general practitioners. An educational
campaign alone does not improve vaccination uptake
significantly.60 Other measures, such as a ‘mobile
cart programme’, using vaccine days in institutions,
peer vaccination, and the use of gift incentives, have
been used with some success.60-62 A better understand-
ing of the knowledge, attitudes, and behaviour of
target groups, as well as novel approaches to pro-
gramme delivery is necessary to improve vaccine
uptake. In the community setting, the perceived
ineffectiveness is best exemplified by reports of
influenza outbreaks in residential homes for the
elderly in Hong Kong during the last influenza
season in 2004 to 2005, despite a territory-wide
campaign by the Department of Health to vaccinate
this target population. The degree of match between
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vaccine strains of viruses and circulating strains could
partly explain the occurrence of these outbreaks.
On a broader perspective, health-care policy
makers need to develop locally relevant and practical
vaccination policies. An example would be the
vaccination of poultry workers in places where
avian influenza is endemic. Health authorities should
ensure that vaccine supplies are adequate for target
populations, especially in unexpected situations
where overall vaccine shortage is imminent.63 The
logistics of vaccinating target groups (in the commu-
nity and health care institutions) should be well
planned, taking into account contingency measures
during pandemic situations. The government’s
preparedness plan for an influenza pandemic is a
good example of this process in action.64 Frontline
doctors and health care workers should realise the
importance of being vaccinated, not only for personal
protection, but also for the protection of patients. In
addition, those working in primary care could further
promote vaccine uptake in the community by provid-
ing adequate information and provision of vaccination,
especially to at-risk populations.
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